Abstract
Résumé
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Canadian Journal of CardiologyReferences
- Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013.Lancet. 2014; 384: 766-781
- Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies.Lancet. 2009; 373: 1083-1096
- A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.Lancet. 2012; 380: 2224-2260
- Lifelong patterns of BMI and cardiovascular phenotype in individuals aged 60-64 years in the 1946 British birth cohort study: an epidemiological study.Lancet Diabetes Endocrinol. 2014; 2: 648-654
- The disproportionate economic burden associated with severe and complicated obesity: a systematic review.Obes Rev. 2013; 14: 883-894
- Low-calorie diets and sustained weight loss.Obes Res. 2001; 9: 290S-294S
- Feasibility and indicative results from a 12-month low-energy liquid diet treatment and maintenance programme for severe obesity.Br J Gen Pract. 2013; 63: e115-e124
- The clinical effectiveness and cost-effectiveness of long-term weight management schemes for adults: a systematic review.Health Technol Assess. 2011; 15: 1-182
- Very-low-calorie diets and sustained weight loss.Obes Res. 2001; 9: 295S-301S
- Long-term weight-loss maintenance: a meta-analysis of US studies.Am J Clin Nutr. 2001; 74: 579-584
- Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study.Lancet Diabetes Endocrinol. 2014; 2: 474-480
- Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment.Diabetes Care. 2013; 36: 2175-2182
- Effects of bariatric surgery on mortality in Swedish obese subjects.N Engl J Med. 2007; 357: 741-752
- Bariatric surgery and long-term cardiovascular events.JAMA. 2012; 307: 56-65
- Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials.BMJ. 2013; 347: f5934
- First report from the American College of Surgeons Bariatric Surgery Center Network: laparoscopic sleeve gastrectomy has morbidity and effectiveness positioned between the band and the bypass.Ann Surg. 2011; 254 (discussion 20-2): 410-420
- Weight recidivism post-bariatric surgery: a systematic review.Obes Surg. 2013; 23: 1922-1933
- 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children.CMAJ. 2007; 176: S1-13
- The importance of caloric restriction in the early improvements in insulin sensitivity after Roux-en-Y gastric bypass surgery.Diabetes Care. 2010; 33: 1438-1442
- Impact of weight-loss medications on the cardiovascular system: focus on current and future anti-obesity drugs.Am J Cardiovasc Drugs. 2007; 7: 273-288
- Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes.N Engl J Med. 2013; 369: 145-154
- Expectations for weight loss and willingness to accept risk among patients seeking weight loss surgery.JAMA Surg. 2013; 148: 264-271
- The role of patients' expectations and goals in the behavioral and pharmacological treatment of obesity.Int J Obes (Lond). 2007; 31: 1739-1745
- Willingness to pay for obesity pharmacotherapy.Obesity (Silver Spring). 2012; 20: 2019-2026
Brown A, Brown I. Patients’ experiences of prescribed anti-obesity drugs and perceptions of support from primary care: a qualitative study. Available at: http://journals.cambridge.org/action/displayAbstract?fromPage=online&aid=7831300&fileId=S1463423610000083. Accessed July 7, 2014.
- Effectiveness of interventions for reducing diabetes and cardiovascular disease risk in people with metabolic syndrome: systematic review and mixed treatment comparison meta-analysis.Diabetes Obes Metab. 2012; 14: 616-625
European Medicines Agency. Committee For Medicinal Products For Human Use (CHMP). Guideline on clinical evaluation of medicinal products used in weight control, November 2007. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003264.pdf. Accessed September 3, 2014.
- Food and Drug Administration's obesity drug guidance document: a short history.Circulation. 2012; 125: 2156-2164
- Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.N Engl J Med. 2010; 363: 905-917
- Effect of bypassing the proximal gut on gut hormones involved with glycemic control and weight loss.Surg Obes Relat Dis. 2012; 8: 371-374
- Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial.Diabetes Obes Metab. 2012; 14: 523-530
- Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease.Int J Obes (Lond). 2014; 38: 1165-1171
- Anti-obesity drugs: past, present and future.Dis Model Mech. 2012; 5: 621-626
- Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass.Diabetologia. 2012; 55: 1890-1901
- Use of prescription antiobesity drugs in the United States.Pharmacotherapy. 2013; 33: 1299-1307
- Comparison of metabolic effects of surgical-induced massive weight loss in patients with long-term remission versus non-remission of type 2 diabetes.Obes Surg. 2012; 22: 910-917
- Obesity in Europe—does anybody care?.Expert Opin Pharmacother. 2013; 14: 971-973
- Systematic review: an evaluation of major commercial weight loss programs in the United States.Ann Intern Med. 2005; 142: 56-66
- Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice.Int J Obes (Lond). 2005; 29: 1153-1167
- Long-term drug treatment for obesity: a systematic and clinical review.JAMA. 2014; 311: 74-86
- Predictors of attrition in bariatric aftercare: a systematic review of the literature.Obes Surg. 2012; 22: 1640-1647
- “Obesity is a disease”: examining the self-regulatory impact of this public-health message.Psychol Sci. 2014; 25: 997-1002
- Early weight loss while on lorcaserin, diet, and exercise as a predictor of week 52 weight-loss outcomes.Obesity (Silver Spring). 2014; 22: 2137-2146
- Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect.J Clin Invest. 2014; 124: 2456-2463
- The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. III: the mechanistic basis for supersensitivity to the LSD stimulus following serotonin depletion.Psychopharmacology (Berl). 1995; 121: 364-372
- Multicenter, placebo-controlled trial of lorcaserin for weight management.N Engl J Med. 2010; 363: 245-256
- Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study.Obesity (Silver Spring). 2012; 20: 1426-1436
- A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults:the BLOSSOM trial.J Clin Endocrinol Metab. 2011; 96: 3067-3077
- XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.Diabetes Care. 2004; 27: 155-161
- Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP).Obesity (Silver Spring). 2012; 20: 330-342
- Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER):a randomised, placebo-controlled, phase 3 trial.Lancet. 2011; 377: 1341-1352
- Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.Lancet. 2010; 376: 595-605
- A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).Obesity (Silver Spring). 2013; 21: 935-943
- Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.Obesity (Silver Spring). 2011; 19: 110-120
- Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes.Diabetes Care. 2013; 36: 4022-4029
- Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.Int J Obes (Lond). 2012; 36: 843-854
- Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study.Int J Obes (Lond). 2013; 37: 1443-1451
Novo Nordisk. Press release. Phase 3a data from largest trial with liraglutide 3 mg demonstrated significantly greater weight loss versus placebo for adults with obesity. Available at: http://www.novonordisk.com/include/asp/exe_news_attachment.asp?sAttachmentGUID=20525a92-b397-4b81-866d-42aae458100f. Accessed July 29, 2014.
- Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs.Obes Rev. 2013; 14: 383-392
Novo Nordisk. Press release. New phase 3a liraglutide 3 mg data showed positive impact on cardiovascular risk markers and fewer people progressing to prediabetes compared with placebo in adults with obesity. Available at: http://www.novonordisk.com/include/asp/exe_news_attachment.asp?sAttachmentGUID=7bfc8e14-21ef-4104-8782-a106be319479. Accessed July 29, 2014.
- Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials.Circ Cardiovasc Imaging. 2013; 6: 560-567
- Eating behavior and glucagon-like peptide-1-producing cells in interposed ileum and pancreatic islets in rats subjected to ileal interposition associated with sleeve gastrectomy.Obes Surg. 2013; 23: 39-49
- How the hindgut can cure type 2 diabetes. Ileal transposition improves glucose metabolism and beta-cell function in Goto-kakizaki rats through an enhanced Proglucagon gene expression and L-cell number.Surgery. 2007; 142: 74-85
- Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin.Synapse. 2001; 39: 32-41
- Pharmacologic treatment options for obesity: what is old is new again.Curr Hypertens Rep. 2013; 15: 182-189
- Topiramate: a new potential pharmacological treatment for obesity.Obes Res. 2004; 12: 167S-173S
- Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors.Prog Retin Eye Res. 2000; 19: 87-112
- GABA(A) receptors in the lateral hypothalamus as mediators of satiety and body weight regulation.Brain Res. 2009; 1262: 16-24
- Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects.Obes Res. 2004; 12: 1658-1669
- Topiramate: effects on cognition in patients with epilepsy, migraine headache and obesity.Ther Adv Neurol Disord. 2013; 6: 211-227
- Neuropsychiatric adverse effects of centrally acting antiobesity drugs.CNS Neurosci Ther. 2011; 17: 490-505
- Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.Am J Clin Nutr. 2012; 95: 297-308
- The Learn Program for Weight Management.American Health Publishing Co, Euless, TX2000
- Cardiovascular safety of phentermine alone. Cardiovascular safety of phentermine alone and in combination with topiramate.Obesity Facts. 2012; 5: 204
- Effects of phentermine and extended-release topiramate alone and in combination on cardiovascular risk factors. Poster 697.Diabetalogia. 2012; 55: S285
- Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity.J Hypertens. 2014; 32: 1178-1188
- Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with type 2 diabetes and normal glucose tolerance.Am J Physiol Endocrinol Metabl. 2012; 303: E122-E131
- Weight loss and cardiovascular risk reduction over 2 years with controlled-release phentermine- topiramate.J Am Coll Cardiol. 2011; 57: E545
- Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial.Addiction. 2004; 99: 1206-1218
- Bupropion treatment of olanzapine-associated weight gain: an open-label, prospective trial.J Clin Psychopharmacol. 2006; 26: 409-413
- Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial.Obes Res. 2002; 10: 633-641
- A controlled trial of naltrexone in obese humans.Int J Obes (Lond). 1985; 9: 347-353
- Effect of naltrexone on senile dementia of the Alzheimer type.J Neurol Neurosurg Psychiatry. 1985; 48: 1169-1171
- Rational design of a combination medication for the treatment of obesity.Obesity (Silver Spring). 2009; 17: 30-39
Orexigen. Press release. Orexigen announces successful interim analysis of Contrave light study. Available at: http://ir.orexigen.com/phoenix.zhtml?c=207034&p=irol-newsArticle&ID=1879629&highlight. Accessed July 21, 2014.
- Incretin-based therapies for type 2 diabetes mellitus.Nat Rev Endocrinol. 2009; 5: 262-269
- Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.BMJ. 2012; 344: d7771
- Incretin hormones and the satiation signal.Int J Obes (Lond). 2013; 37: 1161-1168
- Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase.Drug Metab Dispos. 2010; 38: 1944-1953
- Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.Lancet. 2009; 374: 1606-1616
- First-phase insulin secretion restoration and differential response to glucose load depending on the route of administration in type 2 diabetic subjects after bariatric surgery.Diabetes Care. 2009; 32: 375-380
- Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes.Diabetes Care. 2013; 36: 3276-3282
- Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial.Am Heart J. 2013; 166: 823-830.e5
- Tolerability of nausea and vomiting, and associations with weight loss, in a randomized trial of liraglutide in obese, non-diabetic adults.Int J Obes (Lond). 2013; 38: 689-697
- Cardiovascular biology of the incretin system.Endocr Rev. 2012; 33: 187-215
- A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe?.Diabetes Care. 2013; 36: 2118-2125
- Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed?.BMJ. 2013; 346: f3680
- Vagal nerve dissection during pouch formation in laparoscopic Roux-Y-gastric bypass for technical simplification: does it matter?.Obes Surg. 2009; 19: 412-417
Article info
Publication history
Footnotes
See page 149 for disclosure information.